The prognostic value of inositol polyphosphate 5-phosphatase in cutaneous squamous cell carcinoma - 11/02/19
Abstract |
Background |
Inositol polyphosphate 5-phosphatase (INPP5A) has been shown to play a role in development and progression of cutaneous squamous cell carcinoma (cSCC). The goal of the current study was to explore the prognostic value of INPP5A expression in cSCC.
Methods |
A total of 189 cases of actinic keratosis and SCC in 174 patients were identified; clinical and outcome data were abstracted, histopathology was rereviewed, and immunohistochemical staining and interpretation was performed for INPP5A.
Results |
The majority of tumors (89.4%) had an INPP5A score of 2 or 3. No patients had complete loss of INPP5A. Tumors with an INPP5A score of 1 were more likely to be intermediate- to high-risk tumors (Brigham and Women's Hospital stage ≥T2a 85.0% vs 23.7% [P < .0001]) characterized by a larger diameter (2.4 cm vs 1.3 cm [P = .0004]), moderate-to-poor differentiation (86.7% vs 17.6% [P < .0001]), and perineural invasion (37.5% vs 5.3%, [P < .0001]). An INPP5A score of 1 was associated with a worse 3-year survival (a rate of 42.3% [hazard ratio, 2.81, P = .0006]) and a local metastasis rate of 48.0% (hazard ratio, 4.71; P < .0001).
Conclusions |
Low INPP5A scores are predictive of aggressive tumors and may be a useful adjunct to guide clinical management of cSCC.
Le texte complet de cet article est disponible en PDF.Key words : biomarker, cancer tumor marker, cutaneous squamous cell carcinoma, inositol polyphosphate-5-phosphatase, metastases, outcome, prognosis, prognostic marker, recurrence, squamous cell carcinoma, staging
Abbreviations used : AJCC, AK, BWH, cSCC, HR, IHC, INPP5A, opSCC, SCCIS
Plan
Funding sources: Supported by a Dermatology Foundation Medical Career Development Award (Dr Mangold) and National Institutes of Health grant 5R01CA179157 (Dr Sekulic). |
|
Conflicts of interest: None disclosed. |
|
Presented as an abstract at the 2018 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2018. |
Vol 80 - N° 3
P. 626 - mars 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?